Immunodeficiency 53 (IMD53) Cell Models for Research

Immunodeficiency 53 (IMD53) is a rare primary immunodeficiency disorder caused by mutations in the ZAP70 gene. It is inherited in an autosomal recessive manner. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals worldwide. Clinically, IMD53 presents in infancy with recurrent infections, particularly of the respiratory tract, and is characterized by a selective deficiency of CD8+ T cells, with normal or elevated CD4+ T cells that are functionally impaired. Without early diagnosis and treatment (e.g., hematopoietic stem cell transplantation), the condition is often fatal in the first years of life. The disease is included in the WHO classification of primary immunodeficiencies (PID) and is listed in the Online Mendelian Inheritance in Man (OMIM) as #176977. The clinical impact is severe, with high morbidity and mortality if untreated.

IMD53 serves as an excellent model for studying T cell receptor (TCR) signaling, thymic selection, and the development of CD8+ T cells. The ZAP70 protein is a critical tyrosine kinase in the TCR signaling pathway, and its deficiency leads to a unique immunological phenotype. Researchers can use gene-edited cell models to dissect the molecular mechanisms of ZAP70 function, explore genotype-phenotype correlations, and test therapeutic strategies. Public datasets, such as those from the International Union of Immunological Societies (IUIS) and the European Society for Immunodeficiencies (ESID), provide clinical and genetic data for research. Open questions include the precise role of ZAP70 in T cell development and the potential for gene therapy approaches.

IMD53 is not a cancer, but it involves defective signaling pathways that are also relevant to cancer biology. The primary pathway affected is the TCR signaling cascade:

1. TCR engagement by peptide-MHC complexes triggers activation of Lck, which phosphorylates ITAMs on the CD3 chains.

2. ZAP70 is recruited to the phosphorylated ITAMs via its SH2 domains and is subsequently phosphorylated by Lck.

3. Activated ZAP70 phosphorylates downstream adaptors such as LAT and SLP-76, leading to activation of Ras/MAPK, PLCγ1, and calcium mobilization.

4. These signals ultimately lead to transcription factor activation (NFAT, AP-1, NF-κB) and cytokine production.

In IMD53, loss-of-function mutations in ZAP70 disrupt this cascade, leading to impaired T cell activation and proliferation. This pathway is also critical in certain T cell leukemias and lymphomas, where ZAP70 expression is used as a prognostic marker.

Data from ClinVar and the Human Gene Mutation Database (HGMD).

The main deregulated network is the TCR signaling pathway. Key nodes affected include:

• • ZAP70: central kinase; its loss impairs downstream signaling.
• • LAT and SLP-76: adaptor proteins that are underphosphorylated in ZAP70 deficiency.
• • PLCγ1: reduced activation leads to decreased calcium flux and NFAT activation.
• • Ras/MAPK pathway: impaired, affecting cell proliferation and differentiation.
• • NF-κB: reduced activation, impacting cytokine production.

Additionally, ZAP70 deficiency affects thymic selection, leading to a lack of CD8+ T cells and altered CD4+ T cell function.

Organoids: While organoids are primarily used for epithelial tissues, T cell organoids are emerging as models for studying immune development and function. However, for IMD53, cell lines remain the primary in vitro model.

• • ZAP70 knockout mouse: This model recapitulates the human phenotype, with a lack of CD8+ T cells and impaired TCR signaling. It is widely used to study T cell development and function.
• • ZAP70 mutant mice (e.g., SKG mouse): These mice have a point mutation in ZAP70 that leads to autoimmune arthritis, providing insights into the role of ZAP70 in autoimmunity.
• • Patient-derived xenografts (PDX): Not commonly used for IMD53 due to the rarity and the fact that it is not a cancer, but for studying T cell lymphomas with ZAP70 alterations, PDX models are available.

CRISPR-based gene editing has enabled the creation of isogenic cell lines with specific ZAP70 mutations. These models are invaluable for studying the functional consequences of individual mutations and for drug screening. For example:

• • ZAP70 knockout cell lines: Generated by CRISPR-mediated disruption of the ZAP70 gene in T cell lines (e.g., Jurkat). These lines recapitulate the loss-of-function phenotype and are used to study TCR signaling.
• • ZAP70 point-mutation knock-in lines: Introduced to model specific patient mutations (e.g., R192W, S518R) to assess their impact on kinase activity and signaling.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing consistent and reproducible tools. These models are essential for functional genomics, drug discovery, and precision medicine approaches.

Gene-edited cell lines are used to validate the function of ZAP70 and its interacting partners. For example:

• • Knockout of ZAP70 in Jurkat cells confirms its essential role in TCR-induced calcium flux and IL-2 production.
• • Knock-in of specific mutations allows assessment of their impact on protein stability, kinase activity, and downstream signaling.
• • CRISPR screens can identify modifiers of ZAP70 function, revealing synthetic lethal interactions or compensatory pathways.

Isogenic pairs (wild-type vs. ZAP70 knockout) are used to screen for compounds that can bypass ZAP70 deficiency or restore T cell function. For example:

• • High-throughput screening of small molecules that activate downstream signaling pathways (e.g., PKC activators) may identify potential therapeutic agents.
• • Gene-edited models can be used to test the efficacy of gene therapy approaches, such as lentiviral delivery of functional ZAP70.
• • Resistance mechanisms to drugs targeting TCR signaling can be studied using cells with acquired mutations in ZAP70.

CRISPR-based synthetic lethality screens can identify genes that, when inhibited, selectively kill ZAP70-deficient cells. This approach can uncover novel therapeutic targets for IMD53 and related conditions. Additionally, gene-edited models can be used to identify biomarkers of disease severity or response to therapy.